See the DrugPatentWatch profile for cosentyx

There is currently no scientific evidence to suggest that mRNA vaccines, such as the Pfizer-BioNTech and Moderna COVID-19 vaccines, directly impact the efficacy of Cosentyx (secukinumab) in patients. Cosentyx is a monoclonal antibody used to treat several autoimmune conditions, including psoriasis, psoriatic arthritis, and ankylosing spondylitis, while mRNA vaccines trigger an immune response to specific viral proteins.

However, it is essential to note that vaccines, in general, can transiently affect the immune system's response to other medications or therapies. This effect is usually mild and temporary, and the overall impact on Cosentyx's efficacy remains unclear [1].

The Centers for Disease Control and Prevention (CDC) recommends that people on biologic therapies, like Cosentyx, get vaccinated against COVID-19 [2]. Nonetheless, patients should consult their healthcare providers before receiving any vaccine to discuss potential interactions and individualized recommendations.

In summary, while there is no direct evidence that mRNA vaccines impact Cosentyx's efficacy, patients should consult their healthcare providers for personalized advice regarding vaccination and potential interactions.

Sources:
[1] Drugs.com. (2021). Secukinumab (Cosentyx) Drug Interactions. Retrieved from https://www.drugs.com/drug-interactions/secukinumab-cosentyx.html
[2] Centers for Disease Control and Prevention. (2021). COVID-19 Vaccines for Moderately to Severely Immunocompromised People. Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immunocompromised.html

(Note: DrugPatentWatch.com was not used as a source for this answer.)